Terns Pharmaceuticals, Inc. Book Value per Share Growth

Book Value per Share Growth of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Book Value per Share Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Book Value per Share Growth for the quarter ending March 31, 2022 was -22.43% (a -116.94% decrease compared to previous quarter)
  • Year-over-year quarterly Book Value per Share Growth decreased by -Infinity%
  • Annual Book Value per Share Growth for 2021 was 132.37% (a -91.34% decrease from previous year)
  • Annual Book Value per Share Growth for 2020 was 1528.88% (a -1723.36% decrease from previous year)
  • Annual Book Value per Share Growth for 2019 was -94.18% (a -3.03% decrease from previous year)
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Book Value per Share Growth of Terns Pharmaceuticals, Inc.

Most recent Book Value per Share Growthof TERN including historical data for past 10 years.

Interactive Chart of Book Value per Share Growth of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Book Value per Share Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -22.43%
2021 132.37% 0.0% 0.0% 0.0% 132.37%
2020 0.0% -100.0% -100.0% -100.0% 1528.88%
2019 -100.0% -94.18%
2018 -97.12%

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.